Intensity Therapeutics, Inc. Overview
Pro stress-test →Intensity Therapeutics is a late-stage clinical biotechnology company developing treatments for regional and systemic cancer, with its lead product INT230-6 in Phase 3 studies for soft tissue sarcoma and Phase 2 trials for triple negative breast cancer. The company's DfuseRx platform involves direct tumor injection of a unique combination of cisplatin, vinblastine, and an amphiphilic molecule.
Strategic Profile
Pro stress-test →Intensity's clinical data demonstrates abscopal effects (shrinkage of uninjected tumors) and increased immune activation, suggesting systemic immune engagement following local tumor destruction. The company has successfully extended cash runway and is executing pivotal late-stage trials, positioning itself for potential regulatory milestones in 2026-2027.
Competitive Landscape
Pro stress-test →Competitors in clinical-stage cancer therapeutics include Theriva Biologics and Plus Therapeutics. Intensity's differentiation centers on its localized injection approach with systemic immune activation, targeting underserved cancer indications with limited alternatives.
Industry Context
Intensity Therapeutics, Inc. operates in Biotechnology - Oncology/Cancer Therapeutics.
Key facts
Founded: 2012 · Headquarters: Shelton, Connecticut · Market cap: $19.3M